Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
### Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Reduction of risk of NSAID-associated gastric ulcers
* Zollinger-Ellison syndrome
* H. pylori eradication (in combination with antibiotics)
### Adult Dosing
* **GERD and Erosive Esophagitis:** 40 mg once daily.
* **Healing of Erosive Esophagitis:** 40 mg once daily for up to 8 weeks; may be continued for up to 16 weeks if needed.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg once daily.
* **Reduction of NSAID-associated Gastric Ulcers:** 40 mg once daily, continued for up to 4 weeks.
* **Zollinger-Ellison Syndrome:** Starting dose of 40 mg twice daily. Doses may be adjusted based on individual need, with doses up to 240 mg daily administered intravenously and 400 mg daily orally.
* **H. pylori Eradication:** 40 mg twice daily for 7-14 days in combination with amoxicillin and clarithromycin, or with clarithromycin and metronidazole. Specific regimens vary.
### Pediatric Dosing
* **GERD:**
* **1 to 5 years:** 10 mg once daily for up to 8 weeks.
* **5 to 16 years:** 20 mg once daily for up to 8 weeks.
* Dosing for other indications in pediatric patients is not well-established and may require specialist consultation.
### Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg once daily for moderate to severe hepatic impairment.
* **Renal Impairment:** No dose adjustment necessary.
### Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
### Adverse Effects
* Common: Headache, diarrhea, nausea, dizziness, abdominal pain.
* Long-term use (greater than 1 year) may be associated with an increased risk of:
* Fractures of the hip, wrist, or spine.
* Clostridium difficile-associated diarrhea.
* Vitamin B12 deficiency.
* Hypomagnesemia (can be severe).
### Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, mycophenolate mofetil, and certain HIV medications (e.g., rilpivirine, atazanavir). Separate administration by at least 2 hours.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider dose reduction or temporary discontinuation of PPI.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19 and may affect the metabolism of drugs like clopidogrel.
### Monitoring
* **Magnesium levels:** Particularly with prolonged use (>3 months) or concomitant use of diuretics or digoxin.
* **Bone mineral density:** Consider in patients at risk for osteoporosis.
* **Clinical response:** Assess for symptom improvement and healing of esophagitis.
### Clinical Pearls
* Administer 30-60 minutes before a meal.
* For delayed-release tablets, instruct patients not to crush or chew tablets.
* For oral suspension, reconstitute with water and allow to stand for 5 minutes, then swirl gently before use.
* Long-term use should be re-evaluated regularly to assess the continued need for acid suppression.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines for definitive dosing and management decisions.
